Search

Search Constraints

You searched for: Author/Creator Bazani, Efthymia

Search Results

1. CNS Involvement in AML Patient Treated with 5-Azacytidine. (14th August 2014)

2. Coexistence of Myeloid and Lymphoid Neoplasms: A Single-Center Experience. (3rd November 2019)

3. Cover Image. Issue 2 (13th April 2021)

4. Elevated miR-20b-5p expression in peripheral blood mononuclear cells: A novel, independent molecular biomarker of favorable prognosis in chronic lymphocytic leukemia. (July 2018)

5. MicroRNA-155-5p Overexpression in Peripheral Blood Mononuclear Cells of Chronic Lymphocytic Leukemia Patients Is a Novel, Independent Molecular Biomarker of Poor Prognosis. (31st December 2017)

6. MicroRNA-92a-3p overexpression in peripheral blood mononuclear cells is an independent predictor of prolonged overall survival of patients with chronic lymphocytic leukemia. Issue 3 (23rd February 2019)

7. Treatment with 5-Azacytidine improves clinical outcome in high-risk MDS patients in the 'real life' setting: A single center observational study. Issue 1 (2nd January 2016)

8. Treatment with 5-Azacytidine improves clinical outcome in high-risk MDS patients in the 'real life' setting: A single center observational study. Issue 1 (January 2016)

9. Upregulated hypoxia inducible factor 1α signaling pathway in high risk myelodysplastic syndrome and acute myeloid leukemia patients is associated with better response to 5‐azacytidine—data from the Hellenic myelodysplastic syndrome study group. Issue 2 (1st January 2021)